Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)(Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)) - 药物靶点：CD40L_在研适应症：晚期非小细胞肺癌，转移性非小细胞肺癌，复发性非小细胞肺癌_专利_临床

概要

基本信息

药物类型

肿瘤浸润淋巴细胞

别名

CD40L TIL(H. Lee Moffitt Cancer Center and Research Institute)

靶点

CD40L

作用方式

刺激剂

作用机制

CD40L刺激剂(CD40配体刺激剂)、免疫细胞毒性、T淋巴细胞替代物

治疗领域

肿瘤呼吸系统疾病

在研适应症

晚期非小细胞肺癌转移性非小细胞肺癌复发性非小细胞肺癌

非在研适应症-

原研机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

在研机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的临床试验

NCT05768347

/ Recruiting临床1期IIT

Phase 1 Clinical Trial of Intravesical Adoptive Cell Therapy {ACT) With Tumor Infiltrating Lymphocytes (TIL) for Patients With BCG Exposed High Grade Non-Muscle Invasive Bladder Cancer (NMIBC)

The purpose of the study is to evaluate the feasibility, safety and tolerability of intravesical adoptive cell therapy using TIL (tumor infiltrating lymphocytes) in participants with urothelial cell carcinoma (UCC) non-muscle invasive bladder cancer (NMIBC).

开始日期2023-08-10

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+1]

NCT05681780

/ Recruiting临床1/2期IIT

Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)

To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1, or HER2-genomically altered lung cancer.

开始日期2023-03-10

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

NCT03215810

/ Completed临床1期IIT

A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients With Advanced Non-Small Cell Lung Cancer

Investigators plan to study the safety, side effects, and benefits of tumor-infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases.

开始日期2017-10-11

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+4]

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的临床结果

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的转化医学

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期非小细胞肺癌	临床2期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-03-10
转移性非小细胞肺癌	临床2期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-03-10
复发性非小细胞肺癌	临床2期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-03-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SITC2022	N/A	非小细胞肺癌 PD-1+ \| IFN-Î³	103	tumor-infiltrating lymphocytes (Initial Expansion (IE) TILs)	選獵襯壓築齋製壓鹹網(觸憲選壓窪艱築鹹糧襯) = 願衊顧蓋憲範壓獵鏇獵膚遞積廠鏇選壓獵窪餘 (觸構窪遞糧齋夢簾願襯, 0.02 ~ 30.8) 更多	积极	2022-11-07
SITC2022	N/A	非小细胞肺癌 PD-1+ \| IFN-Î³	103	tumor-infiltrating lymphocytes (Rapid Expansion (REP) TILs)	窪窪築觸築範艱夢襯憲(鹽蓋選壓衊鹽繭鑰鏇願) = 網積繭衊鬱鹽範襯願廠齋遞襯艱鹹範網醖蓋觸 (簾淵淵糧衊簾獵夢鏇鑰 ) 更多	积极	2022-11-07
NCT03215810 (CTgov)	临床1期	腺癌 \| 腺鳞癌 \| 晚期非小细胞肺癌 \| 鳞状细胞癌	20	Tumor-infiltrating Lymphocytes (TIL)+Nivolumab+Fludarabine+CYCLOPHOSPHAMIDE+Tumor-infiltrating Lymphocyte Therapy	構襯遞襯齋繭鏇鏇衊廠(廠齋憲艱餘夢鏇觸蓋網) = 壓遞網鑰觸製壓壓齋餘淵範餘醖築鑰憲窪醖淵 (襯獵憲簾廠構夢積網憲, 餘顧構醖憲鏇網夢繭壓 ~ 願窪遞築鹹糧夢獵夢積) 更多	-	2022-04-13
ASCO2014	临床2期	转移性黑色素瘤	56	Tumor-infiltrating lymphocytes (TIL)	(淵顧鏇願積獵鏇積餘觸) = 積製選夢艱壓鑰範鏇積憲鑰鏇網積獵艱鏇衊築 (製襯顧顧鹽壓選鏇範憲 )	积极	2014-05-20